NewAmsterdam Pharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 months.
- Its last 9 Sell calls were actually followed by a +9% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -42.5% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 10.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -1,002.9% | Better than 3% |
| Net margin | -905.7% | Better than 3% |
| Return on equity | -28.3% | Better than 13% |
| Return on invested capital | -32.1% | Better than 9% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -33.9% | Better than 14% |
| 6-month return | -48.1% | Better than 8% |
| 12-month return (ex latest month) | -48.5% | Better than 3% |
| Distance below 52-week high | 56.4% | Better than 13% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 7.9x | Better than 91% |
| Debt to assets | 0.0% | Better than 99% |
| Interest coverage | -287.0x | Better than 3% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 195.7% | Better than 94% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 19.51
- Open
- 19.21
- Day range
- 18.29 - 19.78
- Avg price
- 18.81
- Volume
- 1.75M
- Turnover
- 32.82M
- Turnover ratei
- 2.13%
- Volume ratioi
- 1.03
- Amplitudei
- 7.66%
- 52-week rangei
- 17.90 - 42.21
Valuation
- P/Ei
- -10.70
- P/E (TTM)i
- -10.89
- P/Bi
- 3.50
- EPSi
- -1.72
- Book value / shi
- 5.26
- Net profit
- -206.28M
- Net assets
- 630.83M
Share structure
- Market cap
- 2.21B
- Float capi
- 1.51B
- Shares out
- 119.93M
- Float sharesi
- 81.84M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
56.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+15.16M net over the window
Short interest
- Shares short
- 12.01M
- % of floati
- 10.05%
- Days to coveri
- 8.32
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of NewAmsterdam Pharma (NAMS)?
NewAmsterdam Pharma last traded at 18.41. This page shows a periodic quote snapshot. Check the displayed quote time.
What is NewAmsterdam Pharma's market cap?
About 2.21B.
What is the P/E ratio of NewAmsterdam Pharma?
The trailing twelve-month P/E is -10.89. The Valuation tab shows it against the stock's own five-year range.
Does NewAmsterdam Pharma pay a dividend?
NewAmsterdam Pharma does not currently pay a regular dividend.
Is NewAmsterdam Pharma a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 54.44, which implies 195.7% upside from the current price. This is not investment advice.
What is NewAmsterdam Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates NewAmsterdam Pharma a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
NewAmsterdam Pharma discussion 0 comments